NewAmsterdam Pharma (NAMS) Accumulated Expenses (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Accumulated Expenses of $5.1 million for Q1 2026, down 66.98% sequentially from $15.4 million in Q4 2025, and down 36.52% YoY from $8.0 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Accumulated Expenses (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Accumulated Expenses for 6 years, with the latest figure at $5.1 million in Q1 2026.
- Quarterly Accumulated Expenses fell 36.52% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (down 36.52% YoY) and the FY2025 annual result came in at $15.4 million, up 13.33% from the prior year.
- Accumulated Expenses fell to $5.1 million in Q1 2026 per NAMS's latest filing, from $15.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $15.4 million in Q4 2025 and troughed at $5.1 million in Q1 2026.
- A 5-year average of $9.9 million and a median of $10.1 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2026: Accumulated Expenses jumped 1197.34% in 2022, then sank 36.52% in 2026.
- Over 5 years, Accumulated Expenses stood at $5.6 million in 2022, then surged by 104.8% to $11.4 million in 2023, then climbed by 19.39% to $13.6 million in 2024, then grew by 13.33% to $15.4 million in 2025, then tumbled by 66.98% to $5.1 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $5.1 million, $15.4 million, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.28 Mn |
| Mar 31, 2026 | 5.09 Mn |
| Dec 31, 2025 | 15.42 Mn |
| Sep 30, 2025 | 10.10 Mn |
| Jun 30, 2025 | 9.46 Mn |
| Mar 31, 2025 | 8.02 Mn |
| Dec 31, 2024 | 13.61 Mn |
| Sep 30, 2024 | 10.58 Mn |
| Jun 30, 2024 | 10.19 Mn |
| Mar 31, 2024 | 9.97 Mn |
| Dec 31, 2023 | 11.40 Mn |
| Dec 31, 2022 | 5.57 Mn |
| Dec 31, 2021 | 428,989.11 |